scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1017308518 |
P356 | DOI | 10.1186/1476-4598-9-28 |
P932 | PMC publication ID | 2828990 |
P698 | PubMed publication ID | 20128926 |
P5875 | ResearchGate publication ID | 41403902 |
P2093 | author name string | Xin Wei | |
David E Green | |||
Aws Abdul-Wahid | |||
Jean Gariépy | |||
Reza Kiarash | |||
Melissa C Cheung | |||
Leigh Revers | |||
Subodini Perampalam | |||
P2860 | cites work | Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I | Q24651553 |
Crystal structure of the holotoxino from Shigella dysenteriae at 2.5 Å resolution | Q27729840 | ||
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
Cancer statistics, 2008 | Q27860585 | ||
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
The S100 protein family: history, function, and expression | Q28293937 | ||
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells | Q28578219 | ||
New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cells | Q30433997 | ||
Probing the surface of eukaryotic cells using combinatorial toxin libraries | Q30699689 | ||
Engineering novel binding proteins from nonimmunoglobulin domains | Q33224761 | ||
The hemolytic uremic syndromes | Q33368547 | ||
Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. | Q34049372 | ||
Ligand-targeted therapeutics in anticancer therapy | Q34152775 | ||
Immunotoxins containing Pseudomonas exotoxin A: a short history | Q35109789 | ||
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia | Q35116184 | ||
Shiga toxins and apoptosis | Q35593092 | ||
Induction of apoptosis by tumor cell-targeted toxins | Q35636355 | ||
Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms | Q35782472 | ||
Ribosome-inactivating proteins | Q35859613 | ||
Management of cutaneous melanoma | Q35877006 | ||
Ribosome inactivating proteins and apoptosis | Q36055888 | ||
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma | Q36781607 | ||
Development trends for monoclonal antibody cancer therapeutics. | Q36790534 | ||
Development trends for new cancer therapeutics and vaccines. | Q37055390 | ||
Melanoma biomarkers: current status and vision for the future. | Q37357928 | ||
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes | Q38426349 | ||
Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases | Q39655730 | ||
Role of caspases in immunotoxin-induced apoptosis of cancer cells | Q40991218 | ||
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44 | Q41652786 | ||
Mutations affecting the activity of the Shiga-like toxin I A-chain | Q44645523 | ||
Production and Characterization of Monoclonal Antibody to a Melanoma Specific Glycoprotein | Q45164578 | ||
Whatever happened to immunotoxins? Research, and hope, are still alive | Q47639092 | ||
A soluble protein characteristic of the nervous system | Q47721048 | ||
Timeline: Chemotherapy and the war on cancer. | Q53313789 | ||
Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. | Q54047541 | ||
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. | Q54083194 | ||
The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. | Q54648744 | ||
Immunotoxin therapy of cancer | Q56454451 | ||
Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma | Q63247804 | ||
Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells | Q73248328 | ||
High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival | Q73685094 | ||
A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer | Q73788268 | ||
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease | Q74099040 | ||
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice | Q74165698 | ||
Shiga toxins | Q74609189 | ||
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients | Q79401099 | ||
P304 | page(s) | 28 | |
P577 | publication date | 2010-02-03 | |
P1433 | published in | Molecular Cancer | Q15724585 |
P1476 | title | An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo | |
P478 | volume | 9 |
Q36222432 | Alterations in the ribosomal machinery in cancer and hematologic disorders. |
Q39367729 | Attempts to express the A1-GMCSF immunotoxin in the baculovirus expression vector system. |
Q33934041 | Design of targeted B cell killing agents |
Q34986254 | Immunotoxins: a promising treatment modality for metastatic melanoma? |
Q33921062 | Interaction of ricin and Shiga toxins with ribosomes |
Q38019016 | Ribosome-inactivating proteins with an emphasis on bacterial RIPs and their potential medical applications. |
Q90629458 | Translation regulation in skin cancer from a tRNA point of view |
Q37954333 | Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy. |
Search more.